Olalla Saad ST[Author] - Search Results

Year	Number of Results
2002	1
2004	1
2008	1
2009	1
2010	3
2011	1
2012	4
2013	5
2014	11
2015	9
2016	6
2017	4
2018	6
2019	6
2020	3
2021	5

1

Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms.

Traina F, Visconte V, Elson P, Tabarroki A, Jankowska AM, Hasrouni E, Sugimoto Y, Szpurka H, Makishima H, O'Keefe CL, Sekeres MA, Advani AS, Kalaycio M, Copelan EA, Saunthararajah Y, Olalla Saad ST, Maciejewski JP, Tiu RV. Traina F, et al. Among authors: olalla saad st. Leukemia. 2014 Jan;28(1):78-87. doi: 10.1038/leu.2013.269. Epub 2013 Sep 18. Leukemia. 2014. PMID: 24045501

2

Artemisinin-type drugs for the treatment of hematological malignancies.

Mancuso RI, Foglio MA, Olalla Saad ST. Mancuso RI, et al. Among authors: olalla saad st. Cancer Chemother Pharmacol. 2021 Jan;87(1):1-22. doi: 10.1007/s00280-020-04170-5. Epub 2020 Nov 3. Cancer Chemother Pharmacol. 2021. PMID: 33141328 Review.

3

An update on arginine in sickle cell disease.

Benites BD, Olalla-Saad ST. Benites BD, et al. Among authors: olalla saad st. Expert Rev Hematol. 2019 Apr;12(4):235-244. doi: 10.1080/17474086.2019.1591948. Epub 2019 Mar 20. Expert Rev Hematol. 2019. PMID: 30855194 Review.

4

LEF1-AS1, long non-coding RNA, inhibits proliferation in myeloid malignancy.

Congrains-Castillo A, Niemann FS, Santos Duarte AS, Olalla-Saad ST. Congrains-Castillo A, et al. Among authors: olalla saad st. J Cell Mol Med. 2019 Apr;23(4):3021-3025. doi: 10.1111/jcmm.14152. Epub 2019 Feb 15. J Cell Mol Med. 2019. PMID: 30770626 Free PMC article.

5

Recombinant erythropoietin as alternative to red cell transfusion in sickle cell disease.

Ferreira FA, Benites BD, Costa FF, Gilli S, Olalla-Saad ST. Ferreira FA, et al. Among authors: olalla saad st. Vox Sang. 2019 Feb;114(2):178-181. doi: 10.1111/vox.12750. Epub 2019 Jan 29. Vox Sang. 2019. PMID: 30695814

6

BRD4 Inhibition Enhances Azacitidine Efficacy in Acute Myeloid Leukemia and Myelodysplastic Syndromes.

Pericole FV, Lazarini M, de Paiva LB, Duarte ADSS, Vieira Ferro KP, Niemann FS, Roversi FM, Olalla Saad ST. Pericole FV, et al. Among authors: olalla saad st. Front Oncol. 2019 Jan 29;9:16. doi: 10.3389/fonc.2019.00016. eCollection 2019. Front Oncol. 2019. PMID: 30761268 Free PMC article.

7

Serine peptidase inhibitor Kunitz type 2 (SPINT2) in cancer development and progression.

Roversi FM, Olalla Saad ST, Machado-Neto JA. Roversi FM, et al. Among authors: olalla saad st. Biomed Pharmacother. 2018 May;101:278-286. doi: 10.1016/j.biopha.2018.02.100. Epub 2018 Feb 27. Biomed Pharmacother. 2018. PMID: 29499401 Review.

8

ANKHD1 is an S phase protein required for histone synthesis and DNA repair in multiple myeloma cells.

Dhyani A, Favaro P, Olalla Saad ST. Dhyani A, et al. Among authors: olalla saad st. Blood Cells Mol Dis. 2020 Sep;84:102460. doi: 10.1016/j.bcmd.2020.102460. Epub 2020 Jun 9. Blood Cells Mol Dis. 2020. PMID: 32562952

9

The challenges of handling deferasirox in sickle cell disease patients older than 40 years.

Ribeiro LB, Soares EA, Costa FF, Gilli SCO, Olalla Saad ST, Benites BD. Ribeiro LB, et al. Among authors: olalla saad st. Hematology. 2019 Dec;24(1):596-600. doi: 10.1080/16078454.2019.1657667. Hematology. 2019. PMID: 31434554

10

ARHGAP21 deficiency impairs hepatic lipid metabolism and improves insulin signaling in lean and obese mice.

Zangerolamo L, Soares GM, Vettorazzi JF, do Amaral ME, Carneiro EM, Olalla-Saad ST, Boschero AC, Barbosa-Sampaio HC. Zangerolamo L, et al. Among authors: olalla saad st. Can J Physiol Pharmacol. 2019 Nov;97(11):1018-1027. doi: 10.1139/cjpp-2018-0691. Epub 2019 Jun 27. Can J Physiol Pharmacol. 2019. PMID: 31247150

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results